49 related articles for article (PubMed ID: 33338248)
1. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
Aliment Pharmacol Ther; 2024 May; ():. PubMed ID: 38695095
[TBL] [Abstract][Full Text] [Related]
2. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD.
Hoyt JE; Teja N; Jiang T; Rozema L; Gui J; Watts BV; Shiner B; Gradus JL
J Dual Diagn; 2022; 18(4):185-198. PubMed ID: 36151743
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.
Graf C; D'Ambrosio R; Degasperi E; Paolucci S; Llaneras J; Vermehren J; Dultz G; Peiffer KH; Finkelmeier F; Herrmann E; Zeuzem S; Buti M; Lampertico P; Dietz J; Sarrazin C
JHEP Rep; 2024 Mar; 6(3):100994. PubMed ID: 38357421
[TBL] [Abstract][Full Text] [Related]
4. Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
Jay JS; Patterson JA; Zhang Y; Ijioma SC; Carroll NV; Holdford DA; Sterling RK; Gupta G; Yakubu I
J Am Pharm Assoc (2003); 2023; 63(6):1700-1705.e4. PubMed ID: 37414279
[TBL] [Abstract][Full Text] [Related]
5. Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021.
Martinez A; Khan T; Dylla DE; Marcinak J; Collins M; Saget B; Conway B
Harm Reduct J; 2023 Oct; 20(1):142. PubMed ID: 37779203
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life.
Pugliese N; Polverini D; Arcari I; De Nicola S; Colapietro F; Masetti C; Ormas M; Ceriani R; Lleo A; Aghemo A
Trop Med Infect Dis; 2023 Nov; 8(11):. PubMed ID: 37999621
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma.
Garza KY; Pandey A; Marzinke MA
J Pharm Biomed Anal; 2023 Oct; 235():115629. PubMed ID: 37619293
[TBL] [Abstract][Full Text] [Related]
8. Profile of Sofosbuvir and Velpatasvir Combination in the Treatment of Chronic Hepatitis C in Children and Adolescents: Current Evidence.
Brigham D; Narkewicz MR
Ther Clin Risk Manag; 2024; 20():1-7. PubMed ID: 38230373
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice.
McEntee S; Liu Y; Mahmoudi T; Oliver K; Cadwell C
Curr Pharm Des; 2023; 29(25):1967-1970. PubMed ID: 37584352
[TBL] [Abstract][Full Text] [Related]
10. Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
Mangia A; Cenderello G; Verucchi G; Ciancio A; Fontana A; Piazzolla V; Minerva N; Squillante MM; Copetti M
World J Clin Cases; 2020 Nov; 8(22):5831-5834. PubMed ID: 33344581
[TBL] [Abstract][Full Text] [Related]
11. Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).
Fagiuoli S; Toniutto P; Coppola N; Ancona DD; Andretta M; Bartolini F; Ferrante F; Lupi A; Palcic S; Rizzi FV; Re D; Alvarez Nieto G; Hernandez C; Frigerio F; Perrone V; Degli Esposti L; Mangia A
Ther Clin Risk Manag; 2023; 19():57-65. PubMed ID: 36699017
[TBL] [Abstract][Full Text] [Related]
12. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.
Wedemeyer H; Di Marco V; Garcia-Retortillo M; Teti E; Fraser C; Morano Amado LE; Rodriguez-Tajes S; Acosta-López S; O'Loan J; Milella M; Buti M; Guerra-Veloz MF; Ramji A; Fenech M; Martins A; Borgia SM; Vanstraelen K; Mertens M; Hernández C; Ntalla I; Ramroth H; Milligan S
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423102
[TBL] [Abstract][Full Text] [Related]
13. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
Sicras-Mainar A; Morillo-Verdugo R
Adicciones; 2022 Nov; 34(4):279-284. PubMed ID: 33338248
[TBL] [Abstract][Full Text] [Related]
14. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection.
Sicras-Mainar A; Morillo-Verdugo R
J Int Med Res; 2020 Oct; 48(10):300060520964659. PubMed ID: 33111612
[TBL] [Abstract][Full Text] [Related]
15. Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.
Mangia A; Scaglione F; Toniutto P; Pirisi M; Coppola N; Di Perri G; Alvarez Nieto G; Calabrese S; Hernandez C; Perrone V; Degli Esposti L; Fagiuoli S
Int J Environ Res Public Health; 2021 Jul; 18(13):. PubMed ID: 34281080
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
[TBL] [Abstract][Full Text] [Related]
17. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Pearlman BL; Hinds AE
Aliment Pharmacol Ther; 2018 Nov; 48(9):914-923. PubMed ID: 30288771
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
